Learn about what’s new in MS research.
This wasn’t a minor complication. It was a version of PML, a brain disease that can be fatal. PML is also a known side effect of Tysabri, so the report of a successful treatment should be important to thousands of MS patients who are being treated with either of those medications.
A case study reported the successful management of a multiple sclerosis (MS) patient who developed a rare condition in the brain — progressive multifocal leukoencephalopathy (PML) — due to treatment with Novartis Pharmaceutical’s Gilenya (fingolimod).
The study, titled “Fingolimod-associated PML with mild IRIS in MS: A clinicopathologic study,” was published in the journal Neurology Neuroimmunology & Neuroinflammation.
It’s about time. Finally, the approval of a medication to treat pediatric-onset MS is here. The number of youngsters who are 10 to 17 and have MS isn’t large, but these young people are just getting started with their lives. It’s time they had a potent medication that might stop their MS progression in its tracks.
Gilenya (fingolimod) has become the first disease-modifying therapy approved by the U.S. Food and Drug Administration (FDA) to treat children and adolescents with relapsing forms of multiple sclerosis (MS).
This expanded approval allows Gilenya, previously indicated for adults patients 18 or older, to be used to treat pediatric relapsing MS patients starting at age 10.
|Read on: MS News: PML Treatment, Gilenya for Kids, Rituximab, a Trial that Is Enrolling|